Skip to main content

Table 3 Clinical and preclinical data related to anti-FGL1 therapy

From: Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Number

Year

Type of tumor

Human/mouse/cell line

Name of FGL1 antibody

Conclusions

References

1

2021

PDAC

Cell lines

FGL1 antibody, (Proteintech)

Anti-FGL1 was associated with lipid metabolism and cell growth in PDAC

[115]

2

2021

HCC

Cell lines

FGL1 antibody, (Proteintech)

Anti-FGL1 eliminated resistance to sorafenib in HCC cells

[116]

3

2020

NSCLC

Cell lines

ab197357 (Abcam)

Anti-FGL1 increased the sensitivity of NSCLC cells to gefitinib

[114]

4

2019

Murine colon adenocarcinoma

Cell lines and mouse model

Anti-mouse FGL1 (clone 177R4)

Both anti-FGL1 and anti-LAG3 mAbs significantly controlled the growth of tumors derived from the MC38 murine colon that were inoculated into syngeneic C57BL/6 mice

[50]

5

2019

Murine liver cell

Cell lines and mouse model

 

Both anti-FGL1 and anti-LAG3 mAbs significantly controlled the growth of tumors derived from established Hepa1-6 murine liver cell lines that were inoculated into syngeneic C57BL/6 mice

 
  1. HCC: hepatocellular carcinoma; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma